PPARs在代谢相关脂肪性肝病中的作用  

Role of PPARs in metabolic associated fatty liver disease

作　　者：姜尧月 李初谊 王秀峰 李斌 卢利霞 张久聪 于晓辉 郑英 JIANG Yaoyue;LI Chuyi;WANG Xiufeng;LI Bin;LU Lixia;ZHANG Jiucong;YU Xiaohui;ZHENG Ying(Department of Gastroenterology,the 940th Hospital of Chinese People′s Liberation Army Joint Logistics Support Force,Lanzhou 730000;The First Clinical Medical College of Gansu University of Traditional Chinese Medicine,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院消化内科,甘肃兰州730000 [2]甘肃中医药大学第一临床医学院

出　　处：《胃肠病学和肝病学杂志》2023年第9期1061-1065,共5页Chinese Journal of Gastroenterology and Hepatology

基　　金：甘肃省非感染性肝病临床医学研究中心(21JR7RA017)。

摘　　要：2020年国际肝病专家组提出,用代谢相关脂肪性肝病(metabolic associated fatty liver disease,MAFLD)替代1980年命名的非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)。现有研究表明,MAFLD发病首要环节是脂质代谢紊乱,过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是调节脂质和糖代谢的关键性受体。MAFLD是近年来最常见的慢性肝病,至少影响全球1/4的成年人,但目前治疗该疾病的相关药物仍然较少。在缺乏特定药物的情况下,使用以PPARs为靶向的中草药治疗MAFLD是一个很有前景的研究方向。本文概述了PPARs在MAFLD中的作用,并总结了以PPARs为靶点治疗MAFLD的中草药,以期为MAFLD的药物开发提供一些参考。In 2020,the International Group of Experts on Liver Disease proposed that metabolic associated fatty liver disease(MAFLD)should be used to replace non-alcoholic fatty liver disease(NAFLD)that has been used since 1980.Recent studies have shown that the primary pathogenesis of MAFLD is lipid metabolism disorder.Peroxisome proliferator-activated receptors(PPARs)are key receptors regulating lipid and glucose metabolism.MAFLD is the most common chronic liver disease in recent years,affecting at least a quarter of adults in the world,but at present,there are still few drugs related to the treatment of the disease.In the absence of specific drugs,the use of PPARs-targeted Chinese herbal medicine for the treatment of MAFLD is a promising research direction.This paper summarized the role of PPARs in MAFLD,and summarized the Chinese herbal medicine targeting PPARs in the treatment of MAFLD,in order to provide some reference for the drug development of MAFLD.

关 键 词：代谢相关脂肪性肝病 过氧化物酶体增殖物激活受体 中草药 

分 类 号：R575[医药卫生—消化系统]